Unicycive Therapeutics Inc (UNCY NASDAQ) stock market data APIs
$4.9427
0.04(0.8%)
as of July 1, 2025
Try our APIs with
free plan!
Unicycive Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies to address unmet medical needs in the United States. Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being developed as a treatment for acute kidney injury; and Renazorb RZB 012 for the treatment of hyperphosphatemia in patients with chronic kidney disease. The company also evaluates licensing of technologies and drugs for orphan diseases, other renal, liver, and other metabolic diseases affecting fibrosis and inflammation. Unicycive Therapeutics, Inc. has license agreements with Shilpa Medicare Ltd to develop and commercialize oxylanthanum carbonate; Sphaera Pharma Pte. Ltd.; Syneos Health LLC to develop of UNI-494; Inotiv for preclinical trial and related services for oxylanthanum carbonate and UNI-494; Lee's Pharmaceutical (HK) Limited; and Lotus International Pte Ltd for the development, registration filing, and approval for oxylanthanum carbonate. The company was incorporated in 2016 and is based in Los Altos, California.
Prev. Close
4.9427
Open
4.9849
High
5.0662
Low
4.7944
52 wk Range
2.02-11
Market Cap
60 904 K
P/E Ratio
0
Shares Outstanding
12 768 K
EPS
-0.61
Beta
2.001
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Unicycive Therapeutics Inc data using free add-ons & libraries
Get Unicycive Therapeutics Inc Fundamental Data
Unicycive Therapeutics Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -30 881 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-14
- EPS/Forecast: -0.1
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Unicycive Therapeutics Inc News
New
Unicycive stock falls as FDA plans complete response letter for OLC
Investing.com - Unicycive Therapeutics Inc (NASDAQ:UNCY) announced that the FDA plans to issue a complete response letter (CRL) for its Oxylanthanum Carbonate (OLC) New Drug Application (NDA). The n...
FDA issues complete response letter for Unicycive's kidney drug
LOS ALTOS, Calif. - Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a small-cap biotech company with a market capitalization of $86 million, announced Monday that the U.S. Food and Drug Administration has...
Unicycive Therapeutics Announces Receipt of Complete Response Letter for Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis
--Complete Response Letter (CRL) cited deficiencies previously identified at a third-party manufacturing vendor unrelated to Oxylanthanum Carbonate (OLC) --No other concerns stated, including pre-cli...
Unicycive Therapeutics to execute 1-for-10 reverse stock split
* Unicycive Therapeutics (NASDAQ:UNCY [https://seekingalpha.com/symbol/UNCY]) plans to implement a 1-for-10 reverse split of the issued shares of its common stock on June 18, 2025. * The common st...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
